X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117) 117
index medicus (93) 93
middle aged (86) 86
male (85) 85
female (84) 84
oncology (84) 84
aged (83) 83
melanoma (83) 83
adult (73) 73
melanoma - drug therapy (52) 52
cancer (46) 46
survival (45) 45
metastasis (40) 40
treatment outcome (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
ipilimumab (34) 34
chemotherapy (30) 30
clinical trials (29) 29
mutation (29) 29
aged, 80 and over (28) 28
care and treatment (28) 28
metastatic melanoma (28) 28
skin neoplasms - drug therapy (28) 28
melanoma - mortality (25) 25
surgery (25) 25
metastases (24) 24
prognosis (24) 24
melanoma - pathology (23) 23
therapy (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
dermatology (22) 22
neoplasm staging (22) 22
patients (22) 22
research (22) 22
vemurafenib (22) 22
analysis (21) 21
melanoma - genetics (21) 21
disease-free survival (20) 20
proto-oncogene proteins b-raf - genetics (20) 20
skin neoplasms - pathology (19) 19
survival analysis (19) 19
young adult (19) 19
immunotherapy (18) 18
italy (18) 18
safety (18) 18
adolescent (17) 17
melanoma - secondary (17) 17
retrospective studies (17) 17
survival rate (17) 17
cancer therapies (16) 16
esophageal cancer (16) 16
risk factors (16) 16
abridged index medicus (15) 15
antibodies, monoclonal - adverse effects (15) 15
follow-up studies (15) 15
skin neoplasms - mortality (15) 15
studies (15) 15
time factors (15) 15
antineoplastic agents - adverse effects (14) 14
medicine, general & internal (14) 14
medicine, research & experimental (14) 14
squamous cell carcinoma (14) 14
antibodies, monoclonal - therapeutic use (12) 12
antineoplastic agents - therapeutic use (12) 12
carcinoma, squamous cell - drug therapy (12) 12
cisplatin - administration & dosage (12) 12
dabrafenib (12) 12
double-blind method (12) 12
drug therapy (12) 12
kaplan-meier estimate (12) 12
skin neoplasms - genetics (12) 12
trial (12) 12
braf (11) 11
carcinoma, squamous cell - pathology (11) 11
cutaneous melanoma (11) 11
hematology, oncology and palliative medicine (11) 11
medical research (11) 11
nivolumab (11) 11
open-label (11) 11
quality of life (11) 11
antibodies, monoclonal - administration & dosage (10) 10
antineoplastic agents - administration & dosage (10) 10
cisplatin (10) 10
disease progression (10) 10
double-blind (10) 10
esophageal neoplasms - drug therapy (10) 10
esophageal neoplasms - pathology (10) 10
mek inhibition (10) 10
melanoma - surgery (10) 10
neoadjuvant therapy (10) 10
patient outcomes (10) 10
proto-oncogene proteins b-raf - antagonists & inhibitors (10) 10
tumors (10) 10
usage (10) 10
combined modality therapy (9) 9
complications and side effects (9) 9
efficacy (9) 9
genetic aspects (9) 9
imidazoles - administration & dosage (9) 9
management (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1345 - 1356
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1480 - 1492
Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and... 
METASTATIC MELANOMA | DABRAFENIB MONOTHERAPY | ONCOLOGY | SAFETY | LONG-TERM SURVIVAL | Analysis | Melanoma
Journal Article